MEP45408A - 6-position substituted indoline, production and use thereof as a medicament - Google Patents

6-position substituted indoline, production and use thereof as a medicament

Info

Publication number
MEP45408A
MEP45408A MEP-454/08A MEP45408A MEP45408A ME P45408 A MEP45408 A ME P45408A ME P45408 A MEP45408 A ME P45408A ME P45408 A MEP45408 A ME P45408A
Authority
ME
Montenegro
Prior art keywords
medicament
production
compounds
position substituted
relates
Prior art date
Application number
MEP-454/08A
Other languages
Bosnian (bs)
Inventor
Armin Heckel
Gerald Juergen Roth
Rainer Walter
Meel Jacobus Van
Norbert Redemann
Ulrike Tontsch-Grunt
Walter Spevak
Frank Hilberg
Original Assignee
Boehringer Ingelheim Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26006858&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MEP45408(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from DE19949208A external-priority patent/DE19949208A1/en
Priority claimed from DE2000142696 external-priority patent/DE10042696A1/en
Application filed by Boehringer Ingelheim Pharma filed Critical Boehringer Ingelheim Pharma
Publication of MEP45408A publication Critical patent/MEP45408A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/32—Oxygen atoms
    • C07D209/34—Oxygen atoms in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Transplantation (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Predmetni pronalazak se odnosi na indolinon supstituisan na poziciji 6 opšte formule (I), u kojoj su R1, R5 i X definisani isto kao u zahtjevu 1, na njegove izomere i na njegove soli, a naročito na njegove fiziološki prihvatljive soli koje imaju vrijedna farmakološka svojstva, a naročito inhibirajuće dejstvo na različite kinaze receptora tirozina i komplekse ciklina/CDK-ova, kao i na proliferaciju endotelijalnih ćelija i različitih ćelija tumora. Pronalazak se takođe odnosi i na ljekove koji sadrže pomenuta jedinjenja, na primjenu pomenutih jedinjenja i na postupak za njihovo dobijanje.The present invention relates to indolinone substituted at the 6-position of the general formula (I), in which R 1, R 5 and X are defined as in claim 1, its isomers and its salts, and in particular its physiologically acceptable salts having valuable pharmacological properties properties, and in particular the inhibitory effect on different tyrosine receptor kinases and cyclin / CDK complexes, as well as on the proliferation of endothelial cells and different tumor cells. The invention also relates to medicaments containing said compounds, to the administration of said compounds, and to a process for their preparation.

MEP-454/08A 1999-10-13 2000-10-09 6-position substituted indoline, production and use thereof as a medicament MEP45408A (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DE19949208A DE19949208A1 (en) 1999-10-13 1999-10-13 New 3-(amino-methylene)-2-indolinone derivatives are kinase inhibitors and cell proliferation inhibitors useful e.g. for treating tumors, metastasis, rheumatoid arthritis or psoriasis
DE2000142696 DE10042696A1 (en) 2000-08-31 2000-08-31 New 3-(amino-methylene)-2-indolinone derivatives are kinase inhibitors and cell proliferation inhibitors useful e.g. for treating tumors, metastasis, rheumatoid arthritis or psoriasis
PCT/EP2000/009867 WO2001027081A1 (en) 1999-10-13 2000-10-09 6-position substituted indoline, production and use thereof as a medicament
YUP-266/02A RS51013B (en) 1999-10-13 2000-10-09 6-position substituted indoline, production and use thereof as a medicament

Publications (1)

Publication Number Publication Date
MEP45408A true MEP45408A (en) 2011-02-10

Family

ID=26006858

Family Applications (1)

Application Number Title Priority Date Filing Date
MEP-454/08A MEP45408A (en) 1999-10-13 2000-10-09 6-position substituted indoline, production and use thereof as a medicament

Country Status (42)

Country Link
EP (2) EP1224170B9 (en)
JP (2) JP4021664B2 (en)
KR (2) KR100835546B1 (en)
CN (1) CN100455568C (en)
AR (1) AR026036A1 (en)
AT (1) ATE439342T1 (en)
AU (1) AU781939B2 (en)
BE (1) BE2015C018I2 (en)
BG (1) BG65983B1 (en)
BR (1) BRPI0014735B8 (en)
CA (1) CA2387013C (en)
CO (1) CO5261488A1 (en)
CY (2) CY1110067T1 (en)
CZ (1) CZ301073B6 (en)
DE (1) DE50015711D1 (en)
DK (1) DK1224170T5 (en)
EA (1) EA006080B1 (en)
EE (1) EE05427B1 (en)
EG (1) EG25931A (en)
ES (1) ES2331459T3 (en)
FR (1) FR15C0024I2 (en)
HK (1) HK1052505B (en)
HR (1) HRP20020306B1 (en)
HU (2) HU230416B1 (en)
IL (2) IL148756A0 (en)
LU (1) LU92681I2 (en)
ME (1) MEP45408A (en)
MX (1) MXPA02002799A (en)
MY (1) MY127956A (en)
NL (1) NL300725I2 (en)
NO (3) NO322746B1 (en)
NZ (1) NZ518489A (en)
PE (1) PE20010671A1 (en)
PL (1) PL207445B1 (en)
PT (1) PT1224170E (en)
RS (1) RS51013B (en)
SA (1) SA01210704B1 (en)
SI (1) SI1224170T1 (en)
SK (1) SK287312B6 (en)
TW (1) TWI268922B (en)
UA (1) UA75054C2 (en)
WO (1) WO2001027081A1 (en)

Families Citing this family (101)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19816624A1 (en) * 1998-04-15 1999-10-21 Boehringer Ingelheim Pharma Novel substituted indolinones, their preparation and their use as pharmaceuticals
KR100600550B1 (en) 2000-10-20 2006-07-13 에자이 가부시키가이샤 Nitrogenous aromatic ring compounds
US6638965B2 (en) 2000-11-01 2003-10-28 Boehringer Ingelheim Pharma Kg Substituted indolinones, preparation thereof and their use as pharmaceutical compositions
DE10117204A1 (en) 2001-04-06 2002-10-10 Boehringer Ingelheim Pharma Indolinones substituted in the 6-position, their preparation and their use as medicaments
ATE343415T1 (en) 2001-06-29 2006-11-15 Ab Science THE USE OF C-KIT INHIBITORS FOR THE TREATMENT OF INFLAMMATORY BOWEL DISEASE
CA2452368A1 (en) 2001-06-29 2003-01-09 Ab Science New potent, selective and non toxic c-kit inhibitors
US20030091974A1 (en) * 2001-06-29 2003-05-15 Alain Moussy Method for screening compounds capable of depleting mast cells
ATE330608T1 (en) 2001-06-29 2006-07-15 Ab Science THE USE OF N-PHENYL-2-PYRIMIDINE-AMINE DERIVATIVES FOR THE TREATMENT OF INFLAMMATORY DISEASES
EP1401413B1 (en) 2001-06-29 2006-11-22 AB Science Use of tyrosine kinase inhibitions for treating allergic diseases
JP2004536097A (en) * 2001-06-29 2004-12-02 アブ サイエンス Uses of tyrosine kinase inhibitors to treat autoimmune diseases
US6765012B2 (en) * 2001-09-27 2004-07-20 Allergan, Inc. 3-(Arylamino)methylene-1,3-dihydro-2H-indol-2-ones as kinase inhibitors
US6797825B2 (en) 2001-12-13 2004-09-28 Abbott Laboratories Protein kinase inhibitors
US20030187026A1 (en) 2001-12-13 2003-10-02 Qun Li Kinase inhibitors
DE60205776T2 (en) 2001-12-27 2006-06-14 Theravance Inc INDOLINONE DERIVATIVE AS PROTEIN KINASE INHIBITOR
SE0302546D0 (en) 2003-09-24 2003-09-24 Astrazeneca Ab New compounds
ITBO20020198A1 (en) * 2002-04-12 2003-10-13 Univ Bologna DERIVATIVES 2, 5 BIS DIAMMINO 1, 4 BENZOCHENIONIC USEFUL FOR THE TREATMENT OF ALZHEIMER DISEASE, METHOD FOR THEIR PREPARATION AND
US7169936B2 (en) 2002-07-23 2007-01-30 Boehringer Ingelheim Pharma Gmbh & Co. Kg Indolinone derivatives substituted in the 6-position, their preparation and their use as medicaments
US7514468B2 (en) 2002-07-23 2009-04-07 Boehringer Ingelheim Pharma Gmbh & Co. Kg Indolinone derivatives substituted in the 6 position, the preparation thereof and their use as pharmaceutical compositions
DE10233500A1 (en) * 2002-07-24 2004-02-19 Boehringer Ingelheim Pharma Gmbh & Co. Kg 3-Z- [1- (4- (N - ((4-methyl-piperazin-1-yl) -methylcarbonyl) -N-methyl-amino) -anilino) -1-phenyl-methylene] -6-methoxycarbonyl- 2-indolinone monoethanesulfonate and its use as a medicament
US20040204458A1 (en) 2002-08-16 2004-10-14 Boehringer Ingelheim Pharma Gmbh & Co. Kg Use of Lck inhibitors for treatment of immunologic diseases
DE10237423A1 (en) * 2002-08-16 2004-02-19 Boehringer Ingelheim Pharma Gmbh & Co. Kg Treating immunological (or related) diseases, e.g. inflammatory bowel disease, rheumatoid arthritis or psoriasis, comprises administration of 3-methylene-2-indolinone derivative or quinazoline compound
US7148249B2 (en) * 2002-09-12 2006-12-12 Boehringer Ingelheim Pharma Gmbh & Co. Kg Indolinones substituted by heterocycles, the preparation thereof and their use as medicaments
JP4879492B2 (en) * 2002-11-27 2012-02-22 アラーガン、インコーポレイテッド Kinase inhibitors for the treatment of diseases
US20050043233A1 (en) * 2003-04-29 2005-02-24 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis
US7683172B2 (en) 2003-11-11 2010-03-23 Eisai R&D Management Co., Ltd. Urea derivative and process for preparing the same
SE0401790D0 (en) * 2004-07-07 2004-07-07 Forskarpatent I Syd Ab Tamoxifen response in pre- and postmenopausal breast cancer patients
US20060058311A1 (en) * 2004-08-14 2006-03-16 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation
EP2364699A1 (en) 2004-09-13 2011-09-14 Eisai R&D Management Co., Ltd. Joint use of sulfonamide based compound with angiogenesis inhibitor
US8772269B2 (en) 2004-09-13 2014-07-08 Eisai R&D Management Co., Ltd. Use of sulfonamide-including compounds in combination with angiogenesis inhibitors
WO2006030826A1 (en) 2004-09-17 2006-03-23 Eisai R & D Management Co., Ltd. Medicinal composition
PE20060777A1 (en) 2004-12-24 2006-10-06 Boehringer Ingelheim Int INDOLINONE DERIVATIVES FOR THE TREATMENT OR PREVENTION OF FIBROTIC DISEASES
EP1925676A4 (en) 2005-08-02 2010-11-10 Eisai R&D Man Co Ltd Method for assay on the effect of vascularization inhibitor
WO2007057397A1 (en) * 2005-11-15 2007-05-24 Boehringer Ingelheim International Gmbh Treatment of cancer
WO2007136103A1 (en) 2006-05-18 2007-11-29 Eisai R & D Management Co., Ltd. Antitumor agent for thyroid cancer
EP1870400A1 (en) * 2006-06-08 2007-12-26 Boehringer Ingelheim Pharma GmbH & Co. KG Salts and crystalline salt forms of an 2-indolinone derivative
WO2008026748A1 (en) 2006-08-28 2008-03-06 Eisai R & D Management Co., Ltd. Antitumor agent for undifferentiated gastric cancer
CN101600694A (en) 2007-01-29 2009-12-09 卫材R&D管理有限公司 Composition for treatment of undifferentiated-type of gastric cancer
EP2167465A1 (en) * 2007-06-12 2010-03-31 Boehringer Ingelheim International GmbH Indolinone derivatives and their use in treating disease-states such as cancer
DK2170827T3 (en) 2007-06-21 2013-11-18 Janssen Pharmaceutica Nv Indoline-2-ones and aza-indoline-2-ones
CA2704000C (en) 2007-11-09 2016-12-13 Eisai R&D Management Co., Ltd. Combination of anti-angiogenic substance and anti-tumor platinum complex
PE20091445A1 (en) * 2007-12-03 2009-10-19 Boehringer Ingelheim Int INDOLINONE DERIVATIVES AND PROCEDURE FOR ITS MANUFACTURE
RU2525114C2 (en) * 2007-12-03 2014-08-10 Бёрингер Ингельхайм Интернациональ Гмбх Method of obtaining indolinone derivative
NZ588957A (en) 2008-06-06 2013-03-28 Boehringer Ingelheim Int Pharmaceutical combination of 3-Z-[1-(4-(N-((4-methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone and N-[4-[2-(2-amino-4,7-dihydro-4-oxo-1H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]-L-Glutamic acid
PE20110213A1 (en) 2008-07-29 2011-04-16 Boehringer Ingelheim Int INDOLINONE DERIVATIVES AS KINASE INHIBITORS
JP2012515184A (en) 2009-01-14 2012-07-05 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング How to treat colorectal cancer
US8802384B2 (en) 2009-03-12 2014-08-12 Boehringer Ingelheim International Gmbh Method or system using biomarkers for the monitoring of a treatment
WO2010108503A1 (en) 2009-03-24 2010-09-30 Life & Brain Gmbh Promotion of neuronal integration in neural stem cell grafts
WO2010130757A1 (en) 2009-05-14 2010-11-18 Boehringer Ingelheim International Gmbh New combination therapy in treatment of oncological and fibrotic diseases
US20120107304A1 (en) 2010-04-27 2012-05-03 Boehringer Ingelheim International Gmbh Combination therapy in treatment of oncological and fibrotic diseases
MX2012014776A (en) 2010-06-25 2013-01-29 Eisai R&D Man Co Ltd Antitumor agent using compounds having kinase inhibitory effect in combination.
WO2012068441A2 (en) 2010-11-19 2012-05-24 Ratiopharm Gmbh Intedanib salts and solid state forms thereof
AU2012246490B2 (en) 2011-04-18 2016-08-04 Eisai R&D Management Co., Ltd. Therapeutic agent for tumor
EP2714937B1 (en) 2011-06-03 2018-11-14 Eisai R&D Management Co., Ltd. Biomarkers for predicting and assessing responsiveness of thyroid and kidney cancer subjects to lenvatinib compounds
WO2013059740A1 (en) 2011-10-21 2013-04-25 Foundation Medicine, Inc. Novel alk and ntrk1 fusion molecules and uses thereof
WO2013112959A1 (en) 2012-01-26 2013-08-01 Angion Biomedica Corp. Antifibrotic compounds and uses thereof
EP2914622B1 (en) 2012-11-05 2023-06-07 Foundation Medicine, Inc. Novel fusion molecules and uses thereof
EP2914621B1 (en) 2012-11-05 2023-06-07 Foundation Medicine, Inc. Novel ntrk1 fusion molecules and uses thereof
CN104936944B (en) 2012-12-06 2017-09-12 山东亨利医药科技有限责任公司 It is used as the dihydroindole ketone derivate of tyrosine kinase inhibitor
KR20150098605A (en) 2012-12-21 2015-08-28 에자이 알앤드디 매니지먼트 가부시키가이샤 Amorphous form of quinoline derivative, and method for producing same
US10980804B2 (en) 2013-01-18 2021-04-20 Foundation Medicine, Inc. Methods of treating cholangiocarcinoma
US20140350022A1 (en) 2013-05-10 2014-11-27 Boehringer Ingelheim International Gmbh Efficacious treatment of NSCLC and predictive clinical marker of the responsiveness of a tumour to a treatment
JP6411379B2 (en) 2013-05-14 2018-10-24 エーザイ・アール・アンド・ディー・マネジメント株式会社 Biomarkers for predicting and assessing responsiveness of endometrial cancer subjects to lenvatinib compounds
CN104003925B (en) * 2013-06-05 2016-03-30 四川大学 Oxindole compounds or derivatives thereof and uses thereof
WO2015009889A1 (en) * 2013-07-18 2015-01-22 Concert Pharmaceuticals, Inc. Deuterated intedanib derivatives and their use for the treatment of proliferative disorders
WO2015017728A1 (en) 2013-07-31 2015-02-05 Windward Pharma, Inc. Aerosol tyrosine kinase inhibitor compounds and uses thereof
ES2926687T3 (en) 2014-08-28 2022-10-27 Eisai R&D Man Co Ltd Highly pure quinoline derivative and method for its production
CN104262232B (en) * 2014-09-09 2016-05-04 苏州明锐医药科技有限公司 The preparation method of Ni Taidani
US20180028662A1 (en) 2015-02-25 2018-02-01 Eisai R&D Management Co., Ltd. Method for Suppressing Bitterness of Quinoline Derivative
CA2978226A1 (en) 2015-03-04 2016-09-09 Merck Sharpe & Dohme Corp. Combination of a pd-1 antagonist and a vegfr/fgfr/ret tyrosine kinase inhibitor for treating cancer
WO2016178064A1 (en) 2015-05-06 2016-11-10 Suven Life Sciences Limited Polymorph of nintedanib ethanesulphonate, processes and intermediates thereof
CN104844499B (en) * 2015-06-05 2017-03-08 北京康立生医药技术开发有限公司 One kettle way prepares the synthetic method of Nintedanib
MX2017015838A (en) * 2015-06-06 2018-08-15 Cloudbreak Therapeutics Llc Compositions and methods for treating pterygium.
CA2988707C (en) 2015-06-16 2023-10-10 Eisai R&D Management Co., Ltd. Combination of cbp/catenin inhibitor and immune checkpoint inhibitor for treating cancer
CN105126909B (en) * 2015-07-13 2018-01-23 淮海工学院 Application of the immobilized palladium catalyst in the synthesis of the nitrobenzene methyl of 4 phenylacetylene base 3
CZ308695B6 (en) 2015-07-29 2021-03-03 Zentiva, K.S. Process for preparing methyl (Z) -3 - [[4- [methyl [2- (4-methyl-1-piperazinyl) acetyl] amino] phenyl] amino] phenylmethylene) -oxindole-6-carboxylate (intedanib, nintedanib)
CN106467500A (en) * 2015-08-14 2017-03-01 廊坊百瑞化工有限公司 A kind of one pot synthesis synthesize the new method of Nintedanib key intermediate
KR20180128390A (en) * 2015-12-24 2018-12-03 레스피버트 리미티드 Indolinone compounds and their use in the treatment of fibrotic diseases
CZ2016104A3 (en) 2016-02-24 2017-09-06 Zentiva, K.S. Crystalline modifications of methyl (3Z)-3- {[(4-{methyl[(4-methylpiperazin-1yl)acetyl]amino}phenyl)amino](phenyl)methylidene}-2oxo-2,3-dihydro-1H-indole-6-carboxylate and the methods of their preparation
EP3426649B1 (en) 2016-03-08 2020-07-22 Respivert Limited Indole derivatives and their use as protein kinase inhibitors
EP3442534A1 (en) 2016-04-13 2019-02-20 Boehringer Ingelheim International GmbH Pharmaceutical combination of nintedanib, trifluridine and tipiracil for treating colorectal cancer
EP3246029A1 (en) 2016-05-19 2017-11-22 Boehringer Ingelheim International Gmbh Pharmaceutical combination of nintedanib and capecitabine for the treatment of colorectal cancer
EP3464240A1 (en) 2016-05-27 2019-04-10 Boehringer Ingelheim International GmbH Use of ecm biomarkers for the determining the treatment onset with nintedanib and pirfenidone
EP3463353A1 (en) 2016-06-01 2019-04-10 Boehringer Ingelheim International GmbH Use of ecm biomarkers for the determining the treatment onset with nintedanib and pirfenidone
BR112018074450A2 (en) 2016-06-02 2019-03-19 Cloudbreak Therapeutics, Llc compositions and methods for using nintedanib to improve the success of glaucoma surgery
EP3490553B1 (en) 2016-07-29 2024-08-28 Oncternal Therapeutics, Inc. Combination comprising an indolinone compound and its use in the treatment of lymphoma
CN106748961A (en) * 2016-11-30 2017-05-31 瑞阳制药有限公司 The impurity compound of Nintedanib, preparation method, using and its detection method
CN106748960A (en) * 2016-11-30 2017-05-31 瑞阳制药有限公司 The potential impurity compound of Nintedanib, preparation method, using and its detection method
CN110062625A (en) 2016-12-12 2019-07-26 勃林格殷格翰国际有限公司 Nintedanib by giving the method for treating interstitial lung disease with Ao Dateluo altogether
WO2018177893A1 (en) 2017-03-28 2018-10-04 Boehringer Ingelheim International Gmbh Nintedanib for use in methods for the treatment of muscular dystrophy
CN111278442B (en) 2017-10-23 2023-06-06 勃林格殷格翰国际有限公司 Novel combinations of active agents for the treatment of progressive fibrotic interstitial lung disease (PF-ILD)
EP3710427B1 (en) 2017-11-17 2023-03-08 Fermion Oy Synthesis of a 2-indolinone derivative known as intermediate for preparing nintedanib
JP7061310B2 (en) * 2018-04-05 2022-04-28 国立大学法人 大分大学 Pharmaceuticals for the prevention and treatment of chronic fatty diseases
CN108358827A (en) * 2018-05-07 2018-08-03 日照市普达医药科技有限公司 It is a kind of to treat psoriasic 2- oxo-indoles analog derivative and preparation method thereof
EP3860976A1 (en) * 2018-10-05 2021-08-11 Ichnos Sciences S.A. Indolinone compounds for use as map4k1 inhibitors
EP4125890A1 (en) 2020-04-01 2023-02-08 Boehringer Ingelheim International GmbH Use of biomarkers in the treatment of fibrotic conditions
CN111848490B (en) * 2020-08-24 2021-09-24 江西国药有限责任公司 Preparation method of high-purity ethanesulfonic acid nintedanib
CN112574094B (en) * 2020-12-14 2022-07-01 成都大学 Indolone derivatives and pharmaceutical use thereof
US20240238368A1 (en) 2021-01-25 2024-07-18 Nibec Co., Ltd. Peptide for preventing and treating fibrosis
EP4098246A1 (en) 2021-05-31 2022-12-07 Lotus Pharmaceutical Co., Ltd. Formulation of nintedanib
CN115703758B (en) * 2021-08-12 2024-03-26 中国医学科学院药物研究所 Compounds used as kinase inhibitors, preparation method and application thereof
WO2024037982A1 (en) 2022-08-16 2024-02-22 Boehringer Ingelheim International Gmbh Pharmaceutical formulations of nintedanib for intraocular use

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL96047C (en) * 1956-06-08
WO1995030420A1 (en) * 1994-05-06 1995-11-16 Alcon Laboratories, Inc. Use of vitamin e tocopheryl derivatives in ophthalmic compositions
US5880141A (en) * 1995-06-07 1999-03-09 Sugen, Inc. Benzylidene-Z-indoline compounds for the treatment of disease
ES2201266T3 (en) * 1996-01-17 2004-03-16 Taiho Pharmaceutical Company Limited INHIBITORS OF THE THREAT OF THE INTIMATE LAYER.
GB9718913D0 (en) 1997-09-05 1997-11-12 Glaxo Group Ltd Substituted oxindole derivatives
DE19815020A1 (en) * 1998-04-03 1999-10-07 Boehringer Ingelheim Pharma New substituted indolinones, their production and their use as medicines
DE19816624A1 (en) * 1998-04-15 1999-10-21 Boehringer Ingelheim Pharma Novel substituted indolinones, their preparation and their use as pharmaceuticals
DE19824922A1 (en) * 1998-06-04 1999-12-09 Boehringer Ingelheim Pharma Novel substituted indolinones, their preparation and their use as pharmaceuticals
GB9904933D0 (en) * 1999-03-04 1999-04-28 Glaxo Group Ltd Compounds

Also Published As

Publication number Publication date
BG106587A (en) 2003-01-31
WO2001027081A1 (en) 2001-04-19
NO20021719L (en) 2002-04-11
IL148756A (en) 2007-10-31
EE200200197A (en) 2003-06-16
LU92681I2 (en) 2015-05-18
AU1023301A (en) 2001-04-23
CZ301073B6 (en) 2009-10-29
YU26602A (en) 2004-11-25
HU230416B1 (en) 2016-05-30
KR20020038949A (en) 2002-05-24
UA75054C2 (en) 2006-03-15
NO2023033I1 (en) 2023-09-05
HUP0204587A2 (en) 2003-05-28
BE2015C018I2 (en) 2019-10-23
SI1224170T1 (en) 2009-12-31
ES2331459T3 (en) 2010-01-05
EP1224170B1 (en) 2009-08-12
SA01210704B1 (en) 2006-12-05
MXPA02002799A (en) 2003-02-27
HRP20020306A2 (en) 2003-10-31
CY2015009I1 (en) 2016-12-14
JP2007302697A (en) 2007-11-22
NO322746B1 (en) 2006-12-04
AU781939B2 (en) 2005-06-23
BG65983B1 (en) 2010-08-31
EP2157081A1 (en) 2010-02-24
IL148756A0 (en) 2002-09-12
KR20070095996A (en) 2007-10-01
HK1052505B (en) 2009-06-26
PT1224170E (en) 2009-10-01
SK6462002A3 (en) 2002-08-06
EP1224170A1 (en) 2002-07-24
DE50015711D1 (en) 2009-09-24
HUS1600022I1 (en) 2017-02-28
HK1052505A1 (en) 2003-09-19
BRPI0014735B1 (en) 2012-07-10
PE20010671A1 (en) 2001-06-28
SK287312B6 (en) 2010-06-07
JP4021664B2 (en) 2007-12-12
EA200200380A1 (en) 2002-10-31
MY127956A (en) 2007-01-31
HUP0204587A3 (en) 2004-07-28
KR100857734B1 (en) 2008-09-10
AR026036A1 (en) 2002-12-26
CZ20021410A3 (en) 2002-07-17
DK1224170T3 (en) 2009-12-07
NO2015009I2 (en) 2015-03-18
HRP20020306B1 (en) 2010-09-30
PL207445B1 (en) 2010-12-31
CN1391557A (en) 2003-01-15
ATE439342T1 (en) 2009-08-15
NO2015009I1 (en) 2015-03-30
LU92681I9 (en) 2019-01-03
BRPI0014735A (en) 2002-07-16
EE05427B1 (en) 2011-06-15
CY2015009I2 (en) 2016-12-14
EG25931A (en) 2012-10-24
BRPI0014735B8 (en) 2021-07-06
PL355433A1 (en) 2004-04-19
CA2387013A1 (en) 2001-04-19
EA006080B1 (en) 2005-08-25
TWI268922B (en) 2006-12-21
NZ518489A (en) 2005-05-27
DK1224170T5 (en) 2018-01-22
JP2003511441A (en) 2003-03-25
NO20021719D0 (en) 2002-04-11
KR100835546B1 (en) 2008-06-09
FR15C0024I1 (en) 2015-04-17
FR15C0024I2 (en) 2016-08-26
RS51013B (en) 2010-10-31
CA2387013C (en) 2009-12-29
CN100455568C (en) 2009-01-28
NL300725I2 (en) 2017-07-13
CO5261488A1 (en) 2003-03-31
EP1224170B9 (en) 2017-11-22
CY1110067T1 (en) 2015-01-14

Similar Documents

Publication Publication Date Title
MEP45408A (en) 6-position substituted indoline, production and use thereof as a medicament
MY122357A (en) Indolinones having kinase inhibitory activity
EE200100184A (en) Novel substituted indolinones for inhibitory activity on a variety of kinases and cyclin / CDK complexes
MY123642A (en) Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, and processes for preparing them.
ME02777B (en) Quinazoline derivatives, medicaments containing said compounds, their utilization and method for the production thereof
TR200003515T2 (en) Substituted indolinone, their manufacture and use as medicines
MEP45508A (en) Bicyclic heterocycles, medicaments containing these compounds, their use and methods for the production thereof
WO1999057117A3 (en) Indole derivatives and their use in the treatment of malignant and other diseases caused by pathological cell proliferation
BR0312648A (en) Process for preparing certain pyrrole triazine compounds
BR0015718A (en) Quinazolines and their use for inhibiting cyclin-dependent kinase enzymes
DK1175398T3 (en) Indoline derivatives as progesterone antagonists
MEP58708A (en) Bicyclic heterocycles, medicaments containing these compounds, their use, and methods for the production thereof
AR025389A1 (en) INDOLINONES REPLACED, THEIR PREPARATION AND THEIR EMPLOYMENT AS MEDICATIONS
HUP0102512A2 (en) Bridged indenopyrrolocarbazoles, process for their preparation, pharmaceutical compositions containing them and their use
BR0208900A (en) Position 6 substituted indolines and their use as kinase inhibitors
SE0104331D0 (en) Novel compounds
WO2001027080A3 (en) 5-substituted indolinones and use thereof as kinase and cyclin/cdk complex inhibitors
CN111732575B (en) N- (3- (pyrimidine-2-yl) phenyl) benzene sulfonamide derivative, pharmaceutical composition, preparation method and application
TNSN07006A1 (en) Novel heterocyclic compounds
BR0312799A (en) Position 6 substituted indolinone derivatives, their preparation and their application as a medicine
HUP0004294A2 (en) Indole derivatives, pharmaceutical compositions containing them and process for producing them
PL84339B1 (en) 1-(2'-cyano-phenoxy)-2-hydroxy-3-ethylamino-propane and salts thereof[us3732277a]
CN109912620B (en) Tetrahydrobenzo [4,5] thieno [2,3-d ] pyrimidine compound and application thereof
BRPI0508706A (en) unusual dichloro-pyrido [2,3-d] pyrimidine derivatives, their manufacture and use as pharmaceutical agents
NO20010513L (en) Novel 2,3,3a, 4,9,9a hexahydro-8-hydroxy-1H-benz [f] indoles, a process for their preparation and their use as medicaments